Market Alert: Putin Meets Trump in Alaska: A Cold Front for Market Volatility or Calm?

Monash IVF Group: FY25 Performance and Outlook

Aug 22, 2025

Monash IVF Group Limited (ASX: MVF) reported FY25 revenue of AU$271.9 million, up 6.7% from the prior year, with underlying EBITDA rising 5.6% to AU$66.3 million. Underlying NPAT was AU$27.4 million, down 8.1% due to weaker domestic IVF volumes and international headwinds, though in line with revised guidance. Reported NPAT improved significantly to AU$25.7 million compared to an AU$5.9 million loss in FY24, which was affected by class action costs.

Operationally, the company strengthened its clinical outcomes, with pregnancy success rates improving to 40.3%, and added 11 new fertility specialists. Domestic stimulated cycles fell 5%, reflecting industry softness, while international cycles dropped 6.4% due to macro conditions. The Women’s Imaging business delivered mixed results, with growth in Melbourne offset by capacity challenges in Sydney. Looking ahead, Monash IVF expects FY26 NPAT of AU$20–23 million amid industry weakness but remains confident in long-term growth, supported by genetics, egg freezing, and expanding patient segments.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com